Cost-effectiveness of general practitioner- versus surgeon-led colon cancer survivorship care: an economic evaluation alongside a randomised controlled trial

[1]  W. Bemelman,et al.  Detection of colon cancer recurrences during follow-up care by general practitioners vs surgeons , 2023, Journal of the National Cancer Institute.

[2]  K. V. van Asselt,et al.  Delivering colon cancer survivorship care in primary care; a qualitative study on the experiences of general practitioners , 2022, BMC Primary Care.

[3]  J. Wind,et al.  Recruitment challenges to the I CARE study: a randomised trial on general practitioner-led colon cancer survivorship care , 2021, BMJ Open.

[4]  R. Verhoeven,et al.  Disease recurrence after colorectal cancer surgery in the modern era: a population-based study , 2021, International Journal of Colorectal Disease.

[5]  J. Twisk.  Analysis of Data from Randomized Controlled Trials , 2021 .

[6]  R. Verhoeven,et al.  Conditional Survival and Cure of Patients With Colon or Rectal Cancer: A Population-Based Study. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  K. V. van Asselt,et al.  Survivorship care for cancer patients in primary versus secondary care: a systematic review , 2020, Journal of Cancer Survivorship.

[8]  M. Heymans,et al.  Taking the Analysis of Trial-Based Economic Evaluations to the Next Level: The Importance of Accounting for Clustering , 2020, PharmacoEconomics.

[9]  Zia Sadique,et al.  EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  A. Hövels,et al.  The Introduction Of A Threshold For The Icer And The Implications For Reimbursement Of Drugs In The Dutch Healthcare System , 2017 .

[11]  Ahmedin Jemal,et al.  Global patterns and trends in colorectal cancer incidence and mortality , 2016, Gut.

[12]  Lena Osterhagen,et al.  Multiple Imputation For Nonresponse In Surveys , 2016 .

[13]  P. Fayers,et al.  Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. , 2016, Journal of clinical epidemiology.

[14]  J. Wind,et al.  Improving care after colon cancer treatment in The Netherlands, personalised care to enhance quality of life (I CARE study): study protocol for a randomised controlled trial , 2015, Trials.

[15]  Manuel Gomes,et al.  A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials , 2014, PharmacoEconomics.

[16]  K. Havenga,et al.  Increased primary health care use in the first year after colorectal cancer diagnosis , 2014, Scandinavian journal of primary health care.

[17]  J. Emery,et al.  The role of primary care in early detection and follow-up of cancer , 2014, Nature Reviews Clinical Oncology.

[18]  K. Augestad,et al.  Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial , 2013, BMJ Open.

[19]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[20]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[21]  M. Neary,et al.  Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.

[22]  C. Silagy,et al.  General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial , 2006, British Journal of Cancer.

[23]  M. Sculpher,et al.  Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. , 2005, Health economics.

[24]  Andrew Briggs,et al.  Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. , 2004, Health economics.

[25]  D. Mant,et al.  Follow-up of breast cancer in primary care vs specialist care: results of an economic evaluation , 1999, British Journal of Cancer.

[26]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.

[27]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.